The First ADC to Win a Survival Battle: What GSK's Ris-Rez Phase 3 Data Mean for the Future of Lung Cancer Treatment

For years, antibody-drug conjugates have been one of oncology's most exciting promises. The concept is elegant: attach a potent cytotoxic payload to an antibody that seeks out a specific protein overexpressed on cancer cells, and you get a guided missile that spares healthy tissue while delivering a lethal dose directly to the tumor. The science has been compelling. The clinical results, in many cases, have been impressive. But one milestone had remained elusive: a Phase 3 trial in which an ADC clearly extended overall survival compared to standard chemotherapy.

That milestone fell on July 10, 2026, when GSK and its Chinese partner Hansoh Pharmaceutical announced that risvutatug rezetecan, known as ris-rez, had met its primary endpoint of overall survival in the ARTEMIS-008 Phase 3 trial in patients with advanced or relapsed small-cell lung cancer. The result was described by GSK as the first positive Phase 3 overall survival data ever reported for a B7-H3-targeted ADC in any tumor type. That is not a narrow claim. It is a landmark.

Why Small-Cell Lung Cancer Matters Here

Small-cell lung cancer is one of oncology's most brutal diseases. It grows fast, spreads early, and responds well to initial platinum-based chemotherapy, only to relapse with a vengeance in the majority of patients. For those who relapse, the options have historically been grim. Topotecan, the standard second-line chemotherapy against which ris-rez was compared in ARTEMIS-008, has been the backbone of relapsed treatment for decades despite modest efficacy and significant toxicity. The arrival of immunotherapy combinations in the first-line setting has improved outcomes somewhat, but the relapsed population remains one of the most underserved in all of oncology.

B7-H3, the protein targeted by ris-rez, is highly expressed in small-cell lung cancer tumors. It also functions as an immune checkpoint, helping tumors evade the body's defenses. That dual role makes it an attractive target: blocking it may both deliver cytotoxic payload and restore some immune surveillance. The ARTEMIS-008 data, while not yet accompanied by specific numerical readouts, showed statistically significant and clinically meaningful improvements in overall survival alongside consistent benefits across secondary endpoints including progression-free survival. No new safety signals were identified.

The Broader Significance of This Win

The importance of this result extends well beyond small-cell lung cancer. The ADC field has been generating impressive response rates and progression-free survival data for years, but overall survival wins in Phase 3 trials have been harder to come by. Regulators and oncologists increasingly want to see that a drug actually helps patients live longer, not just that it delays tumor growth. ARTEMIS-008 provides that evidence for a B7-H3-targeted ADC for the first time.

For GSK, the result validates a strategic bet it made in 2023 when it paid Hansoh $185 million upfront for majority rights to ris-rez outside Greater China. That deal was part of a broader push by GSK, historically known for HIV medicines, respiratory drugs, and vaccines, into oncology. The company has since elevated ris-rez to priority asset status alongside a second Hansoh ADC, mo-rez, which targets B7-H4 and has shown early promise in gynecological cancers. GSK's oncology head Hesham Abdullah has been building the case for both drugs for months, and the ARTEMIS-008 readout is the most significant piece of evidence yet that the investment is paying off.

What Comes Next

The ARTEMIS-008 data will support a regulatory submission in China, where Hansoh holds commercial rights. But the more consequential trial for global markets is the EMBOLD SCLC-301 study, a global Phase 3 trial in relapsed extensive-stage small-cell lung cancer that GSK is running independently. Pivotal data from that trial are expected in 2027. If those results mirror what was seen in China, ris-rez could be on a path to regulatory approval in the United States and Europe, where it already holds FDA Breakthrough Therapy Designation, FDA Orphan Drug Designation, and EMA PRIME Designation for relapsed extensive-stage small-cell lung cancer.

Beyond lung cancer, GSK is advancing ris-rez in prostate cancer and other solid tumors. The B7-H3 target is broadly expressed across multiple cancer types, and the Phase 3 survival win in small-cell lung cancer will likely accelerate investment and trial initiation across that broader program. Abdullah has indicated that several additional Phase 3 trials are expected to begin in the coming months.

There is also a competitive dimension worth watching. Daiichi Sankyo's ifinatamab deruxtecan, another B7-H3-targeted ADC, has been advancing through development in small-cell lung cancer and received FDA Priority Review. The field is moving quickly, and the ARTEMIS-008 result raises the bar for what competitors will need to demonstrate. A survival win in Phase 3 is now the benchmark.

The ADC field has spent years accumulating evidence that these drugs work. ARTEMIS-008 is the moment that evidence crossed into a new category: proof that a B7-H3-targeted ADC can help patients with one of oncology's hardest diseases live longer. That is the kind of data that changes how a drug class is perceived, how it is funded, and ultimately how it is used. The guided missile has found its mark.